Medicine
from24/7 Wall St.
1 day agoEli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank
Eli Lilly has overtaken Novo Nordisk in GLP-1 market leadership driven by tirzepatide’s stronger trial weight-loss results and advancing oral drug candidates.